Remdesivir is least likely to be effective for safe treatment of COVID-19: A pharmacovigilant point of view
preprint
OA: closed
AI-generated summary
This rapid response from May 2020 argues that remdesivir is unlikely to be effective for safe COVID-19 treatment from a pharmacovigilant perspective.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
This manuscript has been published on the 29 th of May 2020 by the honorable BMJ as a rapid response to a related article. However since a DOI has not been assigned and two subsequent manuscripts have cited it, I'm preprinting a copy wishing it might reach all the interested colleagues and researchers in an easier way.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00